Despite major advances in autoimmune treatment, an average 40% of rheumatic patients are non-responders to autoimmune biologics and targeted therapies in clinical trials. Over 70% do not sustain remission in the real world. These patients remain at risk of exposure to unique sensitivities in their exposome that drive worsening symptoms despite prescribed medication.
*Sources: Prime Therapeutics, Inc, CVS Payor Solutions, Published meta analysis of RA, PsA, AS IBM claims data, real world evidence studies & RCTs.
What is Mymee?
Mymee is the first digital care solution proven to help patients experiencing debilitating flares despite autoimmune Rx. Members work with Mymee’s specialized health coaches in a guided personalized trial process. Key components include:
- Patient mobile app customized weekly around unique data capture requirements for testing (e.g. symptoms, exposome variables) & on-demand messaging.
- Data and knowledge management platform to capture, store, manage and analyze data.
- Coach dashboard & tools to manage weekly personalized trial customization and analysis.
How does Mymee help plan members?
Mymee empowers patients with moderate to frequent rheumatic symptoms to significantly improve their quality of life within 17 weeks on average. In peer reviewed studies, >70% patients reversed moderate & severe flares to mild & normal (PROMISⓇ HRQoL).
Members receive:
- Exposome risk analysis (food, environment, Rx) for correlating symptoms to triggers.
- Weekly analysis sessions with certified health coach to guide personalized trials.
- Precision care and nutrition, until they minimize flares while expanding daily activities.
How does Mymee help payers?
Mymee helps payers increase value and lower risks for plan members while reducing healthcare costs. Members report >90% improvement in working with their rheumatologist to optimize autoimmune treatment. Through Mymee, payers saw:
- 45% patients stopped 1 drug or more, and 56% average reduction in steroid use.
- 24% average reduction in biologics, with average gross annual Rx savings of $11,328/per patient on biologics.
- Member satisfaction: Mymee 87 NPS* & 5-star reviews.
*Average Net Promotor Score (NPS) among surveyed autoimmune patients with moderate to high frequency symptoms at baseline, who enrolled in Mymee through a commercial insurer. NPS is a widely used market research metric that is based on a single survey question asking respondents to rate the likelihood that they would recommend a company, product, or a service to a friend or colleague.
Average gross annual Rx savings of $11,328 per patient on biologics defined by payer audited script reduction
Statistically significant and clinically meaningful change among symptomatic patients across 10 HRQoL domains as measured by PROMIS-29. The more severe the symptom, the greater the average improvement
> 40% mean reduction in 59 patient-reported symptoms surveyed in personalized trials
Reduction in average # of prescription drugs among patients who were symptomatic at baseline
Learn more about supporting autoimmune patients through personalized trials & care
Learn more about supporting autoimmune patients through personalized trials & care
Read on for additional articles and insights related to Mymee’s research and use of coach-led personalized trials to guide statistically significant improvements in quality of life.